Center for Translational Cancer Nanomedicine
Vladimir Torchilin, Ph.D., D.Sc.
Nahum Goldberg, M.D.
Project 1: Combined Targeted Micellar Preparations of Novel Proapoptotic Drug and siRNA for Cancer
Project Investigator: Vladimir Torchilin, Ph.D., D.Sc.
This Project will utilize combination nanopreparations containing (1) novel, powerful proapoptotic agents, (2) siRNA to downregulate cancer cell defense mechanisms (such as Pgp), and (3) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a cytokine of the TNFa family. This combination micellar preparation will be modified with a tumor-specific targeting antibody for systemic administration or with the cell-penetrating TAT peptide (TATp) for intratumoral administration.
Project 2: Combined Cancer Therapy with RF Ablation and Drug-Loaded Nanopreparations
Project Investigator: Nahum Goldberg, M.D.
The goal of this Project is to improve tumor destruction by rationally combining minimally invasive image-guided radiofrequency (RF) thermal ablation with nanotherapies. It will use the new nanopreparations to exploit key mechanisms generated by thermal ablation including cell stress and apoptosis, and more peripherally heat shock protein (HSP) production, as well as nanodrug-enhanced RF-induced hyperthermia to overcome multidrug resistance.
Project 3: Multi-Modal Gene Therapy for Pancreatic Cancer Using Targeted Nanovectors
Project Investigator: Mansoor Amiji, Ph.D.
In this Project, targeted nanovectors will encapsulate and deliver combination gene constructs for effective treatment of pancreatic cancer. Safe and effective gelatin-based engineered nanovector systems (GENS) specifically targeted to epidermal growth factor receptors (EGFR) on pancreatic cancer cells will be used to encapsulate and deliver wt-p53 and sFlt-1 expressing genes for maximum therapeutic benefits.
Project 4: Development and High-Throughput Screening of Targeted Anti-Cancer Nanomedicines
Project Investigator: Valery Petrenko, Ph.D., D.Sc.
In this Project, the pharmaceutical nanocarriers - PEGylated "stealth" liposomes encapsulating doxorubicin, paclitaxel, gemcitabine, or vincristin will be targeted to pancreatic and lung tumor cells by cancer cell-specific phage fusion proteins, affinity selected from proprietary phage libraries. Hundreds of "phage-liposome" preparations will then be tested for specific cancer cytotoxicity in a high-throughput format.